INTRODUCTION
Diabetes mellitus represents a significant and growing challenge to healthcare providers in Spain, with a current prevalence of 13.8%, around half of which is undiagnosed, and almost 30% of the population has some form of carbohydrate metabolism disturbance [1] . The disease is associated with a significant clinical burden, both in terms of morbidity and mortality, with 19,518 deaths attributable to diabetes in Spain in 2010 [2] . Further to the clinical burden, the economic burden is also substantial. Current estimates suggest that diabetes is responsible for between 5% and 13% of total healthcare expenditure in most developed countries, and Spain is no exception [2] . Health care expenditure as a result of diabetes mellitus was estimated to be approximately USD 12.5 billion in Spain in 2010 (9% of total healthcare expenditure), and projections suggest that this could increase to approximately USD 16.5 billion in 2030 [3] . The principle driver of this expenditure is diabetesrelated complications.
Whilst maintaining glycemic control forms the cornerstone of diabetes treatment, evidence suggests that controlling other risk factors is also important in reducing the long-term risk of complications. This includes serum lipid levels, blood pressure and body weight. The benefits of multifactorial intervention have been demonstrated in a number of trials, but particularly the Steno-2 study, which compared conventional treatment for multiple risk factors versus intensive multifactorial treatment [4] [5] [6] . Intensive treatment was associated with reduced risk of all-cause mortality, cardiovascular events, retinopathy, neuropathy and end-stage renal disease over 13 years of follow-up. Most long-established diabetes interventions are designed to improve glycemic control, but do little to address other risk factors and meet the multifaceted needs of the type 2 diabetes patient [7] . To meet these complex clinical needs, clinical development programs have targeted the modulation of incretin activity (gastrointestinal hormones involved in the regulation of gut motility, secretion of gastric acid and pancreatic enzymes, gall bladder contraction and nutrient absorption) [8] . This has led to the development of two new classes of antidiabetic therapy: degradation-resistant glucagon-like peptide-1 (GLP-1) receptor agonists, such as liraglutide and exenatide, and inhibitors of dipeptidyl peptidase-4 (DPP-4), such as sitagliptin and vildagliptin. Data from published studies indicate that GLP-1 receptor agonists may be associated with a more substantial reduction in glycated hemoglobin (HbA1c) in comparison with DPP-4 inhibitors (0.5-1.6% reduction versus 0.5-1.0% reduction) [7] . Weight loss has been shown to be associated with liraglutide and exenatide treatment [9] [10] [11] [12] [13] [14] , whereas DPP-4
inhibitors are weight neutral and have been associated only with the prevention of weight gain [15] [16] [17] [18] . (Table 2) . Hypoglycemia rates were similar in the two arms of the trial, although one major hypoglycemic event was reported in the liraglutide arm, but none in the sitagliptin arm. Patients were assumed to receive liraglutide or sitagliptin for 5 years, before intensifying treatment to basal insulin (incretin therapy withdrawn). On treatment intensification, BMI was assumed to return to baseline and hypoglycemia event rates were assumed to be the same, but no other treatment effects were applied.
Model Description
The analysis was performed using the CORE Diabetes Model (IMS Health, Basel, [11, 12] .
Costs and Utilities
Costs were accounted from the perspective of a healthcare payer in Spain (i.e., Sistema Nacional values as required [13] [14] [15] [16] [17] [18] [19] [20] [21] . Health-related 
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This article does not contain any studies with human or animal subjects performed by any of the authors. health-related quality of life, and the cumulative incidence of these complications showed significant reductions in the liraglutide arm. This included macrovascular complications, with the cumulative incidence of myocardial infarction reduced from 27% to 25%, and microvascular complications, with the cumulative incidence of background diabetic retinopathy reduced from 17% to 15%. The only complication that showed an increased incidence in the liraglutide arm was stroke. As well as a reduced incidence of complications, liraglutide was also associated with delayed onset of complications, with the mean time free of all complications increased by almost 7 months. Of particular note was the mean time to onset of stroke, which was delayed by 9 months in the liraglutide arm, demonstrating the influence of the survival paradox.
Direct costs were projected to increase by EUR 2,297 per patient in the liraglutide arm (EUR 54,684 in the liraglutide arm versus EUR 52,387 in the sitagliptin arm) ( Table 3 ; Fig. 2 . Data from the scatterplot was used to generate an acceptability curve, which showed that at a willingness to pay threshold of EUR 30,000 per QALY gained, there was a 73%
probability that liraglutide would be costeffective in comparison with sitagliptin.
Sensitivity Analyses
Sensitivity analyses found that costeffectiveness outcomes were most sensitive to changes in the HbA1c benefit associated with liraglutide (Table 4) Interestingly, over a 30-year time horizon, the ICER was lower than in the base case analysis (50-year time horizon). This is due to the increased survival in the liraglutide arm, increasing mean life expectancy, and therefore greater costs are accrued in the liraglutide arm in the later years of the analysis. Altering the discount rate also reflected the long-term benefits associated with liraglutide, with incremental quality-adjusted life expectancy increasing to 0.29 QALYs and incremental costs falling to EUR 1,877 when a discount rate of 0% was used. Changing the timing of treatment switching led to changes in the ICER.
It was found to increase when patients received incretin therapy for 7 years, due to the increased acquisition costs of liraglutide, and fell when treatment switching was brought forward. Increasing the cost of complications led to a small decrease in the ICER, whilst the converse was true when the cost of complications was reduced.
Switching patients to liraglutide after 1 year of sitagliptin treatment was found to improve clinical outcomes compared to remaining on sitagliptin. Mean life expectancy was increased by 0.11 years, and quality-adjusted life expectancy by 0.13 QALYs (Table 4) 
DISCUSSION
The liraglutide with sitagliptin, as this is the most commonly prescribed dose in Europe. However, a 1.8 mg daily dose is also available, and data from the clinical trial published by Pratley et al. [9] suggest that the higher dose may be associated with greater clinical benefits than the 1.2 mg dose.
Whilst metformin remains the first-line therapy option for patient with type 2 diabetes, modulation of incretin activity, through addition of a GLP-1 receptor agonist or a DPP-4 inhibitor, represents a potential second-line therapy option for patients failing to achieve glycemic control on metformin monotherapy. The GLP-1 receptor agonists and DPP-4 inhibitors offer alternatives to longstanding second-line treatment options, such as sulphonylureas (associated with increased risk of hypoglycemic events and modest weight gain) or thiazolidinediones (associated with cardiovascular risk, weight gain, edema and fractures) [25] . Modern treatment of type 2 diabetes is based around maintaining glycemic control, but also addressing the comorbidities associated with diabetes, specifically obesity, hypertension and dyslipidemia and the trial data published by Pratley et al. [9] suggest that liraglutide and sitagliptin may be useful in terms of managing a variety of risk factors.
Through maintaining this multifactorial control, the risk of long-term diabetes-related complications can be reduced, thereby reducing the burden of diabetes. The present analysis found that liraglutide was associated with reduced cumulative incidence and delayed onset of neuropathy compared to sitagliptin. There is evidence from animal models suggesting that increased circulating GLP-1 (either through administration of a DPP-4 inhibitor or a GLP-1 receptor agonist) may reduce neuropathy, independent of glycemic control [27] .
However, this research is at a very early stage, and how the potential benefit will manifest in humans, rather than animals is, as yet, with sitagliptin [29, 30] . Weight loss with sitagliptin was a little better in the Pratley et al. [9] trial than in previous studies where it has been generally shown to be weight neutral. [33] . The Glycemia Reduction Approaches in Diabetes (GRADE) study will aim to provide long-term data on the relative effectiveness of diabetes medications in patients failing metformin therapy, including liraglutide and sitagliptin [34] . This 5,000-patient, 7-year study will provide a wealth of data for health economic analysis, and will be a key data source for future economic evaluation when the study reports in 2020.
CONCLUSION
The recent 26-week study investigating the safety and efficacy of liraglutide and sitagliptin published by Pratley et al. [9] indicated that liraglutide was associated with greater improvements from baseline HbA1c, total cholesterol and BMI compared to sitagliptin. Long-term projections of this short-term trial data using a recently validated model suggest that liraglutide is likely to improve survival, reduce complication rates and be cost-effective from the perspective of a healthcare payer in Spain.
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